It may be safe to discontinue or deescalate antibiotics in some cancer patients who develop febrile neutropenia (FN) before the condition resolves, but guidelines and studies aren’t yet fully conclusive, a panel of speakers said during the Hematology/Oncology Pharmacy Association’s 2021 virtual annual conference.
Marked by fever and absolute neutrophil count (ANC) of less than 500 cells/mm3, the incidence of FN varies between 10% and 50% in solid tumors and is reportedly greater than